SCHEMBL4833064

SCHEMBL4833064

COc1ccc2cc(C(=O)N(C)OC)ccc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.64
CLK1 P49759 1/20 0.57
DYRK1A Q13627 1/20 0.57
DYRK1B Q9Y463 1/20 0.57
CYP1A2 P05177 3/20 0.54
ALDH1A1 P00352 1/20 0.54
HPGD P15428 1/20 0.54
CYP2C19 P33261 1/20 0.54
HSD17B10 Q99714 1/20 0.54
PLAU P00749 1/20 0.50
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 1/20 0.47
MLYCD O95822 1/20 0.46
PTGS1 P23219 3/20 0.46
AKR1C3 P42330 3/20 0.46
AKR1C2 P52895 3/20 0.46
CYP2A6 P11509 1/20 0.46
HSD17B1 P14061 1/20 0.46
HSD17B2 P37059 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515914 0.86 CES2 (0.53) KDM4EALDH1A1HPGDHSD17B10PLAU
SCHEMBL286256 0.85 CES2 (0.57) KDM4ECLK1DYRK1ADYRK1BCYP1A2
SCHEMBL13694026 0.83 MLYCD (0.44) KDM4ECLK1DYRK1ADYRK1BHPGD
SCHEMBL192728 0.83 NCEH1 (0.54) KDM4ECLK1DYRK1ADYRK1BPLAU
SCHEMBL13694024 0.83 MLYCD (0.48) KDM4ECLK1DYRK1ADYRK1BCYP1A2
SCHEMBL307622 0.83 CES2 (0.62) KDM4ECLK1DYRK1ADYRK1BCYP1A2
SCHEMBL2652683 0.82 HPGDS (0.67)
SCHEMBL19763355 0.81 MLYCD (0.45) KDM4ECLK1DYRK1ADYRK1BCYP1A2
SCHEMBL3149026 0.80 LCK (0.49) KDM4EALDH1A1HPGDHSD17B10PLAU
SCHEMBL2653922 0.80 MLYCD (0.58) KDM4ECLK1DYRK1ADYRK1BPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449484-B2 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-11 US disclosed
EP-1343779-B1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-27 EP disclosed
US-20060166988-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2006-07-27 US disclosed
US-6861417-B2 Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines SMITHKLINE BEECHAM CORPORATION (US) 2005-03-01 US disclosed
US-20040053943-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2004-03-18 US disclosed
EP-1343779-A4 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
US-20040014973-A1 Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines SMITHKLINE BEECHAM CORPORATION 2004-01-22 US disclosed
EP-1126852-B1 PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINES SMITHKLINE BEECHAM CORP (US) 2004-01-21 EP disclosed
EP-1343779-A2 NOVEL COMPOUNDS SmithKline Beecham Corporation (US) 2003-09-17 EP disclosed
US-6548503-B1 2-(4-Fluorophenyl)-3-(pyridin-4-yl)pyrazine for example; inhibits p38 kinases; cytokine suppressive anti-inflammatory drugs SMITHKLINE BEECHAM CORPORATION 2003-04-15 US disclosed
EP-1126852-A4 PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINES SMITHKLINE BEECHAM CORP (US) 2002-07-03 EP disclosed
WO-2002039954-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2002-05-23 WO disclosed
EP-1126852-A1 PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINES SmithKline Beecham Corporation (US) 2001-08-29 EP disclosed
WO-2000025791-A1 PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINES SMITHKLINE BEECHAM CORPORATION (US) 2000-05-11 WO disclosed
US-5739336-A SELECTIVE 5-HYDROXYTRYPTAMINE-2C RECEPTOR ANTAGONISTS SYNTEX (U.S.A.) INC. (US) 1998-04-14 US disclosed
WO-1997000872-A1 1,3,8-TRIAZA- AND 3,8-DIAZA-1-OXASPIRO(4,5)DECANE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 1997-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053943-A1 Novel compounds TIE1, TEK, VEGFA KDM4E 3105/4885CLK1 4394/4885DYRK1A 3904/4885
US-20060166988-A1 Novel compounds TIE1, TEK, VEGFA KDM4E 3105/4885CLK1 4394/4885DYRK1A 3904/4885
US-20040014973-A1 Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines TK2, TYMP, MPL KDM4E 2383/4885CLK1 4795/4885DYRK1A 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.